AIQQX
Price
$21.27
Change
+$0.08 (+0.38%)
Updated
Jun 2 closing price
Net Assets
461.74M
VFFSX
Price
$373.03
Change
+$0.50 (+0.13%)
Updated
Jun 2 closing price
Net Assets
1.6T
Interact to see
Advertisement

AIQQX vs VFFSX

Header iconAIQQX vs VFFSX Comparison
Open Charts AIQQX vs VFFSXBanner chart's image
AIQQX vs VFFSX Comparison Chart in %
View a ticker or compare two or three
VS
AIQQX vs. VFFSX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AIQQX is a Hold and VFFSX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VFFSX has more cash in the bank: 1.6T vs. AIQQX (462M). AIQQX pays higher dividends than VFFSX: AIQQX (1.62) vs VFFSX (1.04). AIQQX was incepted earlier than VFFSX: AIQQX (10 years) vs VFFSX (10 years). AIQQX (0.70) is less costly to investors than VFFSX (0.01). AIQQX is a more actively managed with annual turnover of: 13.00 vs. VFFSX (2.00). AIQQX has a lower initial minimum investment than VFFSX: AIQQX (0) vs VFFSX (5000000000). VFFSX annual gain was more profitable for investors over the last year : 28.07 vs. AIQQX (-0.11). VFFSX return over 5 years is better than : 81.48 vs. AIQQX (16.34).
AIQQXVFFSXAIQQX / VFFSX
Total Expense Ratio0.690.016,900%
Annual Report Gross Expense Ratio0.700.017,000%
Fund Existence10 years10 years-
Gain YTD0.52211.2105%
Front LoadN/AN/A-
Min. Initial Investment05000000000-
Min. Initial Investment IRAN/AN/A-
Net Assets462M1.6T0%
Annual Yield % from dividends1.621.04156%
Returns for 1 year-0.1128.07-0%
Returns for 3 years23.9277.6731%
Returns for 5 years16.3481.4820%
Returns for 10 yearsN/A263.64-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NFGC2.050.06
+3.02%
New Found Gold Corp
IMNN2.160.01
+0.47%
Imunon Inc
FE45.32-0.06
-0.13%
FirstEnergy Corp
TORO5.07-0.01
-0.14%
Toro Corp
VKTX29.29-1.98
-6.33%
Viking Therapeutics